U.S. Pharmaceutical — Operating Income
McKesson U.S. Pharmaceutical — Operating Income remained flat by 0.0% to $1.00B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 43.6%, from $696.50M to $1.00B. Over 4 years (FY 2021 to FY 2025), U.S. Pharmaceutical — Operating Income shows an upward trend with a 9.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved operational efficiency, better pricing power, or higher volume, while a decrease suggests margin compression or rising operating costs.
Detailed definition
This metric measures the profitability of the U.S. Pharmaceutical segment derived from its core distribution and service...
Peer comparison
Comparable to 'Segment Operating Profit' or 'Segment EBIT' reported by major competitors in the pharmaceutical wholesale and distribution industry.
mck_segment_u_s_pharmaceutical_operating_incomeHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $2.76B | $2.88B | $3.21B | $2.79B | $4.00B |
| YoY Change | — | +4.2% | +11.4% | -13.1% | +43.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — operating income?
- McKesson (MCK) reported u.s. pharmaceutical — operating income of $1.00B in Q4 2025.
- How has McKesson's u.s. pharmaceutical — operating income changed year-over-year?
- McKesson's u.s. pharmaceutical — operating income increased by 43.6% year-over-year, from $696.50M to $1.00B.
- What is the long-term trend for McKesson's u.s. pharmaceutical — operating income?
- Over 4 years (2021 to 2025), McKesson's u.s. pharmaceutical — operating income has grown at a 9.7% compound annual growth rate (CAGR), from $2.76B to $4.00B.
- What does u.s. pharmaceutical — operating income mean?
- The profit generated by the U.S. pharmaceutical business segment from its core operations.